NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Akcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in USEuropean regulators have recommended a licence for Akcea and Ionis’ ultra-rare disease drug Waylivra, a therapy that the Share XAkcea/Ionis’ rare disease drug Waylivra set for EU market after rejection in UShttps://pharmaphorum.com/news/akcea-ionis-rare-disease-drug-waylivra-set-for-eu-market-after-rejection-in-us/
Novartis licenses lipoprotein-lowering CVD drugExcited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment Share XNovartis licenses lipoprotein-lowering CVD drughttps://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/
Eyeing Novartis deal, Akcea trumpets lipoprotein drug dataIonis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with Share XEyeing Novartis deal, Akcea trumpets lipoprotein drug datahttps://pharmaphorum.com/news/eyeing-novartis-deal-akcea-trumpets-lipoprotein-drug-data/
